Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Farmers Insurance
Fish and Richardson
Cipla
Dow
Cantor Fitzgerald
US Army
Mallinckrodt
Argus Health

Generated: September 19, 2018

DrugPatentWatch Database Preview

ZYPREXA RELPREVV Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Zyprexa Relprevv patents expire, and what generic alternatives are available?

Zyprexa Relprevv is a drug marketed by Eli Lilly Co and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in ZYPREXA RELPREVV is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.

Drug patent expirations by year for ZYPREXA RELPREVV
Generic Entry Opportunity Date for ZYPREXA RELPREVV
Generic Entry Date for ZYPREXA RELPREVV*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for ZYPREXA RELPREVV
10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-, 4,4'-methlenebis(3-hydroxy-2-naphthalenecarboxylate) (1:1), monohydrate
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine pamoate monohydrate
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine 4,4'-Methylenebis[3-hydroxy-2-naphthalenecarboxylate] Monohydrate
221373-18-8
4-[(3-CARBOXY-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLIC ACID 5-METHYL-8-(4-METHYLPIPERAZIN-1-YL)-4-THIA-2,9-DIAZATRICYCLO[8.4.0.0(3),?]TETRADECA-1(14),2,5,7,10,12-HEXAENE HYDRATE
4,4'-Methylenebis[3-hydroxy-2-naphthalenecarboxylic Acid compound with 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine Hydrate
AKOS016340342
D06623
FT-0673224
J-014547
KS-00002WVM
KS-1403
MolPort-035-395-288
Olanzapine pamoate
Olanzapine pamoate (USAN)
Olanzapine pamoate [USAN]
Olanzapine Pamoate Hydrate
Olanzapine pamoate monohydrate
PL050720
SCHEMBL1635524
UNII-X7S6Q4MHCB
X7S6Q4MHCB

US Patents and Regulatory Information for ZYPREXA RELPREVV

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-001 Dec 11, 2009 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-002 Dec 11, 2009 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-003 Dec 11, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for ZYPREXA RELPREVV

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-001 Dec 11, 2009 ➤ Sign Up ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-003 Dec 11, 2009 ➤ Sign Up ➤ Sign Up
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-002 Dec 11, 2009 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for ZYPREXA RELPREVV

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,617,321 2-methyl-thieno-benzodiazepine formulation ➤ Sign Up
7,303,764 2-methyl-thieno-benzodiazepine formulation ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for ZYPREXA RELPREVV

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB96/058 United Kingdom ➤ Sign Up PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
70015 Netherlands ➤ Sign Up PRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
C0012 Belgium ➤ Sign Up PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Farmers Insurance
Fish and Richardson
Cipla
Dow
Cantor Fitzgerald
US Army
Mallinckrodt
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.